Notably, the nasal priming with the PSPF T-dependent antigen co-administered with the respiratory commensal bacterium or the CP-derived BLPs efficiently stimulated humoral and cellular immunity and increased the resistance to primary pneumococcal challenge, as well as the secondary pneumococcal infection induced after the inflammatory lung damage mediated by the activation of TLR3. This evidence concerns the gene CP and pneumococcal infection.